Clinical trials: Chemoradiotherapy-Related Toxicity
Toxicity, Drug
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Neoadjuvant chemoradiotherapy followed by surgery has been the standard modality for locally advance esophageal carcinoma. According to CROSS study, the pathological complete remission rate achieved by paclitaxel and carboplatin…
- Trial name
- NCT05355168
- Testing
- neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Anhui Provincial Hospital
Rectal Cancer, Locally Advanced Rectal Cancer
A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue
This clinical study investigates the anti-inflammatory and anti-cancer properties of a high-bioavailability formulation of curcumin (BCM-95) in patients with mid-to-low rectal cancer receiving neoadjuvant chemoradiotherapy…
- Conditions
- Rectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis, Radiation Proctitis
- Trial name
- BCMRECRAD (NCT07248020)
- Testing
- Curcumin (BCM-95®)
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Cancer
Predictive Modelling for Patient Stratification According to Treatment-related Toxicity and Survival After Chemoradiation for Head and Neck Cancer
Radiotherapy is an integral component of the current multimodality treatment approach in locally advanced head and neck cancer (HNC).
- Trial name
- PRETOXIS (NCT02103010)
- Where
- 2 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Lung Cancer
3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy
Primary Objective: Developing Common Toxicity Criteria (CTC) 3.0 grade > 3 treatment related pneumonitis (TRP) or Developing local-regional recurrence among patients treated with 3D conformal radiation therapy (CRT) (Arm 1) or…
- Trial name
- NCT00520702
- Testing
- Intensity Modulated Radiation Therapy, 3-Dimensional Conformal Radiation Therapy
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Drug-Related Side Effects and Adverse Reactions
Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma
This study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT03177174
- Testing
- Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Luo yanrong
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Mediastinal Lymphoma, Hodgkin Lymphoma
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
Malignant anterior mediastinal tumors essentially include lymphomas and thymomas. The location of mediastinum is anatomically close to several critical organs such as heart, lung, and breasts, which might be affected meaningfully…
- Conditions
- Mediastinal Lymphoma, Hodgkin Lymphoma, Non Hodgkin Lymphoma
- Trial name
- NCT03969693
- Testing
- Standard treatment protocol with combined chemoradiation
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Chang Gung Memorial Hospital
Cardiotoxicity, Lung Cancer Stage III
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer.
- Conditions
- Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
- Trial name
- CLARITY (NCT04305613)
- Testing
- Chemoradiation
- Where
- 8 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer of Cervix
Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix
A study to evaluate the efficacy of concomitant chemoradiation as compared to radiotherapy alone. Concomitant chemoradiation is not a new treatment modality for carcinoma cervix.
- Trial name
- CRACx (NCT00193791)
- Testing
- CT + RT
- Where
- India
- Volunteers
- 850 people
- Sponsor
- Tata Memorial Hospital
Cancer Patients Receiving Chemotherapy or Chemoradiotherapy
Nutrition Intervention During Chemotherapy
Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival.
- Trial name
- NCT01871350
- Testing
- Daily intake for 10 weeks (+/- 2 weeks)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Non-small Cell Lung Cancer, Cardiac Toxicity
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent…
- Trial name
- NCT06277388
- Testing
- Impedance cardiography
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Sun Yat-sen University
Anal Cancer, Colorectal Cancer
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea.
- Conditions
- Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
- Trial name
- NCT00075868
- Testing
- octreotide acetate
- Where
- 112 sites in United States
- Volunteers
- 233 people
- Sponsor
- Radiation Therapy Oncology Group
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center